Enveloped Virus-like Particle Technology Platform Prepares COVID-19 Vaccine Study
Massachusetts-based VBI Vaccines Inc. recently announced updated clinical and preclinical data from its coronavirus program, VBI-2900, which consists of three vaccine candidates derived from the Company's proprietary enveloped virus-like particle (eVLP) technology platform.
The initial clinical study of VBI-2901 is expected to initiate during the summer of 2022.
As of April 5, 2022, this development program includes the following:
- VBI-2902: A monovalent candidate directed against the ancestral/Wuhan SARS-CoV-2 strain,
- VBI-2905: A monovalent candidate directed against the Beta SARS-CoV-2 variant,
- VBI-2901: A trivalent, pan-coronavirus candidate targeting SARS-CoV-2 (COVID-19), SARS-CoV, and MERS-CoV.
Dr. Melanie Saville, Executive Director of Vaccine R&D, CEPI, commented in a related VBI press release, "Over the last two years, we have seen the persistent evolution of SARS-CoV-2."
"To stay one-step ahead of SARS-CoV-2 variants and other deadly coronaviruses, the world must invest in multivalent, broadly protective coronavirus vaccine technologies—like the eVLP technology being advanced by VBI."
The clinical and preclinical data for all three vaccine candidates have continued to support the robust potential of the eVLP platform, with candidates that have been able to elicit broad immune responses against coronaviruses says the Company.
The VBI-2900 program is supported by a partnership with CEPI, with a contribution of up to $33 million, and the Government of Canada through its Strategic Innovation Fund, with an award of up to CAD $56 million, which was recently extended through the end of 2023.
An additional contribution of up to CAD $1 million from a collaboration with the National Research Council of Canada.
Note: This news article edited VBI's press statement for clarity and was manually edited for mobile readership.